Prior notification of a concentration (Case M.9274 — GlaxoSmithKline/Pfizer Consumer Healthcare Business) (Text with EEA relevance.)

C 181/8 EN Official Journal of the European Union 27.5.2019 Prior notification of a concentration (Case M.9274 — GlaxoSmithKline/Pfizer Consumer Healthcare Business) (Text with EEA relevance) (2019/C 181/04) 1. On 17 May 2019, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1). This notification concerns the following undertakings: — GlaxoSmithKline plc. (‘GSK’, United Kingdom), and — Pfizer Consumer Healthcare Business (‘Pfizer CH’, United States), controlled by Pfizer Inc. GSK acquires within the meaning of Article 3(1)(b) of the Merger Regulation sole control over the whole of Pfizer CH. The concentration is accomplished by way of purchase of shares and assets. 2. The business activities of the undertakings concerned are: — GSK is a global pharmaceutical company active in the research, development, manufacturing, and marketing of prescription pharmaceuticals, vaccines, and consumer healthcare pharmaceuticals typically available without prescription, for various indications. GSK’s worldwide consumer health products span across various therapeutic areas, including pain management, respiratory health, nutrition and digestive health, skin health, and oral health. — Pfizer CH develops, manufactures and markets non-prescription medicines, vitamins, and nutritional products globally. Pfizer CH is active worldwide across various product categories, including pain management,...